NEWS・COLUMN
We send the latest information from SMC Laboratories.
STZ: Type 1 or Type 2 Diabetes?
When discussing our unique NASH-HCC model STAM with clients, we are so often asked: What type of diabetes does the streptozotocin induce? Since streptozotocin (an N-acetyl-β-D-glucosaminidase inhibitor; STZ) is cytotoxic to pancreatic beta cells, STZ-induced diabetes models are often considered as a model for Type 1 diabetes mellitus (T1D) which is in definition caused…
Lung fibrosis in COVID-19
COVID-19 is now being recognized as a multi-organ disease that causes not only pneumonia, but also cause damage to other organs such as the liver, kidney and intestines. Recent reports have focused on lung fibrosis. COVID-19 develops via infection with a virus belonging to the beta-coronavirus class, similar to the virus that…
ENYO Pharma announces positive Vonafexor (EYP001) results for the LIVIFY phase 2a study in F2-F3 NASH patients over 12 weeks
ENYO Pharma (France) announced on 28 July, 2021, positive Vonafexor (EYP001) results for the LIVIFY phase 2a study in F2-F3 NASH patients over 12 weeks. For detailed information, see the URL below. https://www.businesswire.com/news/home/20210728005557/en/ENYO-Pharma-Announces-Positive-Vonafexor-EYP001-Results-for-the-LIVIFY-Phase-2a-Study-in-F2-F3-NASH-Patients-over-12-weeks Vonafexor is a synthetic non-steroidal, non-Bile Acid, highly selective FXR agonist. This is used the STAM™ mouse model for non-clinical…
New Partnership with cancer model search service Repositive, Inc.
SMC Laboratories, Inc. is pleased to announce a partnership with Repositive, Inc., a UK-based bespoke cancer model search service. Repositive supports researchers working in oncology to find the right cancer models for their studies. They also organise and curate cancer model data from partner CROs, and present this inventory of models online, via their beta…
Amplia Therapeutics has publshed a pres releaes regarding the AMP945 and AMP886 efficacy evaluation study for NASH we have provied.
Amplia Therapeutics, which is our client, has announced the results of pharmacology study using a STAM™ mouse model. For detail information, see the Amplia's press release. https://www.ampliatx.com/site/PDF/fd3f2d1f-9d2b-4fff-a6ad-13a3ea8d4956/ATXFAKInhibitorsReduceFibrosisinAnimalModelofNASH
Chemomab announces enrollment of first patient in phase 2a study of CM-101 in NASH
Chemomab Ltd.(Israel) announced on 26 April, 2021, enrollment of first patient in phase 2a study of CM-101 in NASH. For detailed information, see the below URL. https://www.prnewswire.com/news-releases/chemomab-announces-enrollment-of-first-patient-in-phase-2a-study-of-cm-101-in-non-alcoholic-steatohepatitis-nash-301276524.html?tc=eml_cleartime CM-101, a monoclonal antibody designed to bind and block CCL24 activity. The antibody used the STAM™ mouse model for non-clinical studies, and data showing the improvement…
Wnt/β-catenin in our NASH-HCC model: How does it correlate to human liver cancer?
The main cause of hepatocellular carcinogenesis today is chronic liver disease following HCV and HBV infection. By virtue of recent advances in treatment methods, the number of patients with HCC caused by these infections is expected to decrease in the future. On the other hand, the number of patients with NAFLD and NASH is…
CohBar, Inc. announces the completion of enrolment in the Phase 1b stage of the CB4211 clinical study of NASH and obesiy.
CohBar, Inc. (USA) announced on March 29, 2021, that the completion of enrolment in the Phase 1b stage of the CB4211 clinical study of NASH and obesity. For detail information, see the CohBar's press release. https://www.cohbar.com/news-media/press-releases/detail/143/cohbar-completes-enrollment-in-the-phase-1b-clinical-trial CB4211 is a first-in-class mitochondria based therapeutic. The peptide used the STAM™ mouse model for non-clinical studies,…
Gannex Announces Positive Clinical Results in Overweight and Obese Subjects for Its THR-b Agonist ASC41
Gannex (Shanghai, China) has announced positive clinical results in overweigth and obse subjects for its THR-b agonist ASC41. For detail information, see the Gannex's press release. https://www.ascletis.com/news_detail/175/id/462.html
TERNS announces FDA clearance of investigational new drug application for first-in-human phase 1 trial of TERN-501, its THR-beta agonist in development for the treatment of NASH
TERNS Pharmaceuticals, Inc. (USA) has announced FDA clearance of investigational new drug aplication for first-in-human phase 1 trial of TERN-501, its THR-beta agonist in development for the treatment of NASH. For detail information, see the TERNS's press release. https://ir.ternspharma.com/news-releases/news-release-details/terns-announces-fda-clearance-investigational-new-drug-ind
Inventiva announces design of Phase III clinical trial with Ianifibranor in NASH
Inventiva (France) has announced design of Phase III clinical trial with Ianifibranor in NASH For detail information, see the Inventiva's press release. https://www.globenewswire.com/news-release/2021/01/05/2153793/0/en/Inventiva-announces-design-of-Phase-III-clinical-trial-with-lanifibranor-in-NASH.html
Hepion pharma announces positive top line data for low dose CRV431 in Phase 2a "AMBITION' clinical trial for treatment of advanced NASH.
Hepion pharma (NJ), which is our client, has announced positive top line data for low dose CRV431 in Phase 2a “AMBITION” clincal trial for treatment of advanced NASH. CRV431 is a cyclophillin inhibitor. The compound has been used in nonclinical pharmacology study using the STAMTM mouse model and has been shown to improve liver…